Clinical implications of an analysis of pharmacokinetics of crizotinib coadministered with dexamethasone in patients with non-small cell lung cancer.

Lin, Swan; Nickens, Dana J; Patel, Maulik; Wilner, Keith D; Tan, Weiwei

Lin, Swan; Nickens, Dana J; Patel, Maulik; Wilner, Keith D; Tan, Weiwei.

Affiliation

Lin S; Clinical Pharmacology, Global Product Development, Pfizer Inc, 10555 Science Center Drive, CB10/002/2533, San Diego, CA, 92121, USA.
Nickens DJ; Clinical Pharmacology, Global Product Development, Pfizer Inc, 10555 Science Center Drive, CB10/002/2533, San Diego, CA, 92121, USA.
Patel M; Clinical Pharmacology, Global Product Development, Pfizer Inc, 10555 Science Center Drive, CB10/002/2533, San Diego, CA, 92121, USA.
Wilner KD; Oncology, Global Product Development, Pfizer Inc, 10555 Science Center Drive, San Diego, CA, 92121, USA.
Tan W; Clinical Pharmacology, Global Product Development, Pfizer Inc, 10555 Science Center Drive, CB10/002/2533, San Diego, CA, 92121, USA. weiwei.tan@pfizer.com.

Cancer Chemother Pharmacol ; 84(1): 203-211, 2019 07.

Article de En | MEDLINE | ID: mdl-31127319

Sujet(s)
Mots clés

CYP3A inducers; Crizotinib; Dexamethasone; Non-small cell lung cancer; Targeted therapy

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Dexaméthasone / Protocoles de polychimiothérapie antinéoplasique / Carcinome pulmonaire non à petites cellules / Crizotinib / Tumeurs du poumon Limites: Humans Langue: En Journal: Cancer Chemother Pharmacol Année: 2019 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google